SEHK:2162Biotechs
Keymed Biosciences (SEHK:2162) Loss Narrowing In 1H 2025 Tests Premium Growth Narrative
Keymed Biosciences (SEHK:2162) has just posted FY 2025 first half revenue of C¥498.8 million with a basic EPS loss of C¥0.30 per share, while trailing twelve month figures show revenue of C¥716.3 million and a basic EPS loss of C¥1.91. Over recent reporting halves, the company has seen revenue move from C¥54.7 million in 1H 2024 to C¥373.4 million in 2H 2024 and then to C¥498.8 million in 1H 2025, alongside basic EPS losses of C¥1.29, C¥0.68 and C¥0.30 respectively. These figures place the...